



Teva Pharmaceuticals USA, Inc.

**URGENT DRUG RECALL**  
**Metoprolol Succinate Extended-Release Tablets, USP**  
**25 mg, 50 mg, 100 mg, 200 mg**  
**January 29, 2026**

Metoprolol Succinate Extended-Release Tablets 25 mg			
NDC	Lot #	Exp. Date	Size
45963-709-11	0715J251	12/2026	100 Count
45963-709-11	0716J251	01/2027	100 Count
45963-709-11	0717J251	01/2027	100 Count
45963-709-96	0715J252	12/2026	1000 Count
45963-709-96	0716J252	01/2027	1000 Count
45963-709-96	0717J252	01/2027	1000 Count

Metoprolol Succinate Extended-Release Tablets 50 mg			
NDC	Lot #	Exp. Date	Size
45963-676-11	0486G251	01/2027	100 Count
45963-676-11	0487G251	01/2027	100 Count
45963-676-11	0488G251	01/2027	100 Count
45963-676-96	0486G252	01/2027	1000 Count
45963-676-96	0487G253	01/2027	1000 Count
45963-676-96	0488G252	01/2027	1000 Count

Metoprolol Succinate Extended-Release Tablets 100 mg			
NDC	Lot #	Exp. Date	Size
45963-677-11	0718J251	12/2026	100 Count
45963-677-11	0729J251	12/2026	100 Count
45963-677-11	0730J251	12/2026	100 Count
45963-677-96	0718J252	12/2026	1000 Count
45963-677-96	0729J252	12/2026	1000 Count
45963-677-96	0730J252	12/2026	1000 Count

Metoprolol Succinate Extended-Release Tablets 200 mg			
NDC	Lot #	Exp. Date	Size
45963-678-11	0686H251	02/2027	100 Count
45963-678-11	0687H251	02/2027	100 Count
45963-678-11	0688H251	02/2027	100 Count

Dear Valued Customer:

Teva Pharmaceuticals USA, Inc. (Teva USA) is initiating a voluntary nationwide recall of the above twenty-one (21) lots of Metoprolol Succinate Extended-Release Tablets, USP 25 mg, 50 mg, 100 mg and 200 mg to the RETAIL LEVEL. The product in this recall is distributed under the Teva Pharmaceuticals USA, Inc. label. The reason for the recall is out-of-specification (OOS) dissolution result, associated with these specific lots. The main safety concern that may potentially arise from the out-of-specification (OOS) dissolution result may impact drug release and consequent absorption. Extended-release formulations rely on controlled dissolution to maintain therapeutic plasma concentrations over 24 hours. Out-of-specification dissolution results may suggest altered drug release, potentially leading to reduced efficacy and poor disease control. According to the Health Hazard Assessment by Teva USA, exposure to the product of concern could lead to moderate adverse events and the likelihood of the harm was assessed as remote. The overall risk of harm in the patient population is low.

This recall is being made with the knowledge of the U.S. Food and Drug Administration.

**Please take the following actions upon receipt of this letter:**

- Immediately examine your inventory for the twenty-one (21) lots of Metoprolol Succinate Extended-Release Tablets, USP 25 mg, 50 mg, 100 mg and 200 mg listed above.
- Immediately discontinue distribution of and quarantine twenty-one (21) lots of Metoprolol Succinate Extended-Release Tablets, USP 25 mg, 50 mg, 100 mg and 200 mg listed above.
- Teva USA's records indicate that the recalled lot was commercially distributed/shipped to its direct customers from 09/08/2025 through 12/15/2025.
- **If you have further distributed twenty-one (21) lots of Metoprolol Succinate Extended-Release Tablets, USP 25 mg, 50 mg, 100 mg and 200 mg listed above, please perform a SUB-RECALL to your sub-accounts using this Recall Notification and Business Reply Form (BRF) as a basis for your recall notification.**

Promptly complete the attached Recall BRF, even if you have no product to return. Please note: The Recall BRF must be filled out. If the Recall BRF form is not filled out correctly and, in its entirety, no credit will be issued. Please return the completed Recall BRF in its entirety



Teva Pharmaceuticals USA, Inc.

**URGENT DRUG RECALL**  
**Metoprolol Succinate Extended-Release Tablets, USP**  
**25 mg, 50 mg, 100 mg, 200 mg**  
**January 29, 2026**

to Inmar, Attention: Recall Coordinator, by any one of these means:

MAIL: Inmar, One West Fourth Street, Suite 500, Winston Salem, NC 27101

EMAIL: [rxrecalls@inmar.com](mailto:rxrecalls@inmar.com).

FAX: 817-868-5362

After receipt of your Recall BRF, Inmar will send labels for your Return Goods Authorization (RGA) and shipping of your product return. Products returned that are not the subject of the recall will not be credited and will be destroyed.

<b>CONTACT INFORMATION AND CREDIT</b>
<p><b>Product Returns:</b> Contact Inmar at 877-692-8378 (Hours of Operation: M – F, 9.00 am to 5.00 pm Eastern Time) for Recall Stock Response forms or acquire from: <a href="http://clsnetlink.com">clsnetlink.com</a></p>
<p><b>Medical-related Questions or to report an Adverse Event:</b> Contact Teva Medical Information at: 888-838-2872, option 3, then option 4 Live calls received: M - F, 9:00 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week or by email at <a href="mailto:druginfo@tevapharm.com">druginfo@tevapharm.com</a></p>
<p><b>Product Quality Complaint-related Questions:</b> Contact Teva Quality Assurance Services: 888-838-2872, option 4 Live calls received: M - F, 9:00 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week or by email at <a href="mailto:QAS.QAS@tevapharm.com">QAS.QAS@tevapharm.com</a></p>
<p><b>Customer Service-related Questions:</b> Contact Teva Customer Service: 888-838-2872, option 3, then option 2 Live calls received: M - F, 8:30 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week</p>
<p><b>FDA contact information for reporting adverse events/quality complaints:</b> Online at <a href="http://www.fda.gov/medwatch/report.htm">www.fda.gov/medwatch/report.htm</a> or call FDA at 1-800-FDA-1088</p>

Sincerely,

Regulatory Compliance, Teva Pharmaceuticals USA, Inc.



Teva Pharmaceuticals USA, Inc.

**URGENT DRUG RECALL**  
**Metoprolol Succinate Extended-Release Tablets, USP**  
**25 mg, 50 mg, 100 mg, 200 mg**  
**January 29, 2026**

**RECALL BUSINESS REPLY FORM**

Date Form Completed \_\_\_\_\_

**This form must be filled out completely. If this form is not filled out correctly and, in its entirety, no credit will be issued. Promptly return your completed Business Reply Form (BRF) by any one of these means to Inmar, Attn: Recall Coordinator**  
**MAIL: Inmar, 1 W 4th St., Winston Salem, NC 27101 EMAIL: [rxrecalls@inmar.com](mailto:rxrecalls@inmar.com) FAX: 817-868-5362**

**Section 1 – Customer Information**

This Stock Response is for (Check One):

Teva Direct Account  Non-Direct Customer

Customer/Store Name: \_\_\_\_\_ Address (Street/City/State/Zip): \_\_\_\_\_

\*DEA #: \_\_\_\_\_ \*Debit Memo #: \_\_\_\_\_  
*\*DEA # is required; in order to process your form. \*Debit Memo # is required; in order to process your form.*

Contact Name (please print): \_\_\_\_\_ Telephone #: \_\_\_\_\_

Please mark your answer - I have checked my stock and:

I **do** have stock of the recalled item(s) (complete section 2) OR  I **do not** have stock of the recalled item(s).

**Teva Direct Accounts**

Does your response include all your DC locations?  YES  NO  
Did you communicate the recalls to your direct accounts  YES  NO

**Non-Direct Customer**

The product(s) in this recall were purchased from: \_\_\_\_\_  
Name of Your Wholesaler/Distributor and Location

**Section 2 – Quantity of Product to Return**

Enter the information of the recalled product(s) to be returned in the table below. If additional space is needed, please make copies of this form.

NDC #	Lot #	Exp Date	Size	Quantity of Product to Return (Count Partial Bottles as 1)
45963-709-11	0715J251	12/2026	100 Count	
45963-709-11	0716J251	01/2027	100 Count	
45963-709-11	0717J251	01/2027	100 Count	
45963-709-96	0715J252	12/2026	1000 Count	
45963-709-96	0716J252	01/2027	1000 Count	
45963-709-96	0717J252	01/2027	1000 Count	
45963-676-11	0486G251	01/2027	100 Count	
45963-676-11	0487G251	01/2027	100 Count	
45963-676-11	0488G251	01/2027	100 Count	
45963-676-96	0486G252	01/2027	1000 Count	
45963-676-96	0487G253	01/2027	1000 Count	




Teva Pharmaceuticals USA, Inc.

**URGENT DRUG RECALL**  
**Metoprolol Succinate Extended-Release Tablets, USP**  
**25 mg, 50 mg, 100 mg, 200 mg**  
**January 29, 2026**

NDC #	Lot #	Exp Date	Size	Quantity of Product to Return (Count Partial Bottles as 1)
45963-676-96	0488G252	01/2027	1000 Count	
45963-677-11	0718J251	12/2026	100 Count	
45963-677-11	0729J251	12/2026	100 Count	
45963-677-11	0730J251	12/2026	100 Count	
45963-677-96	0718J252	12/2026	1000 Count	
45963-677-96	0729J252	12/2026	1000 Count	
45963-677-96	0730J252	12/2026	1000 Count	
45963-678-11	0686H251	02/2027	100 Count	
45963-678-11	0687H251	02/2027	100 Count	
45963-678-11	0688H251	02/2027	100 Count	

Images Shown Have Not Been Reproduced to Scale of Actual Labels





Teva Pharmaceuticals USA, Inc.

# URGENT DRUG RECALL

## Metoprolol Succinate Extended-Release Tablets, USP

25 mg, 50 mg, 100 mg, 200 mg  
January 29, 2026

NDC 45963-676-96

**Metoprolol Succinate Extended-Release Tablets, USP**

**50 mg\***

Rx only  
1,000 Tablets

teva

CTIN 0034596367692

**\*Each Film-Coated Tablet Contains:**  
47.66 mg of metoprolol succinate, USP equivalent to 50 mg of metoprolol tartrate, USP.

Dispense in a tight, light-resistant container as defined in the USP.

**Usual Dosage:** See accompanying literature for full prescribing information.

Store at 25°C (77°F); with excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**Keep this and all medications out of the reach of children.**

Manufactured In Bulgaria By: Balkanpharma Dupnitsa AD, Dupnitsa 2600, Bulgaria, Rev. A 8/2023

Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054

52-0763

Lot/Exp/Serialization Coding Area

NDC 45963-677-11

**Metoprolol Succinate Extended-Release Tablets, USP**

**100 mg\***

Rx only  
100 Tablets

teva

CTIN 0034596367712

**\*Each Film-Coated Tablet Contains:**  
95.33 mg of metoprolol succinate, USP equivalent to 100 mg of metoprolol tartrate, USP.

Dispense in a tight, light-resistant container as defined in the USP.

**Usual Dosage:** See accompanying literature for full prescribing information.

Store at 25°C (77°F); with excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**Keep this and all medications out of the reach of children.**

Manufactured In Bulgaria By: Balkanpharma Dupnitsa AD, Dupnitsa 2600, Bulgaria, Rev. A 8/2023

Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054

52-0764

Lot/Exp/Serialization Coding Area

NDC 45963-677-96

**Metoprolol Succinate Extended-Release Tablets, USP**

**100 mg\***

Rx only  
1,000 Tablets

teva

CTIN 0034596367969

**\*Each Film-Coated Tablet Contains:**  
95.33 mg of metoprolol succinate, USP equivalent to 100 mg of metoprolol tartrate, USP.

Dispense in a tight, light-resistant container as defined in the USP.

**Usual Dosage:** See accompanying literature for full prescribing information.

Store at 25°C (77°F); with excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**Keep this and all medications out of the reach of children.**

Manufactured In Bulgaria By: Balkanpharma Dupnitsa AD, Dupnitsa 2600, Bulgaria, Rev. A 8/2023

Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054

52-0765

Lot/Exp/Serialization Coding Area

NDC 45963-678-11

**Metoprolol Succinate Extended-Release Tablets, USP**

**200 mg\***

Rx only  
100 Tablets

teva

CTIN 0034596367819

**\*Each Film-Coated Tablet Contains:**  
190.65 mg of metoprolol succinate, USP equivalent to 200 mg of metoprolol tartrate, USP.

Dispense in a tight, light-resistant container as defined in the USP.

**Usual Dosage:** See accompanying literature for full prescribing information.

Store at 25°C (77°F); with excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**Keep this and all medications out of the reach of children.**

Manufactured In Bulgaria By: Balkanpharma Dupnitsa AD, Dupnitsa 2600, Bulgaria, Rev. A 8/2023

Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054

52-0766

Lot/Exp/Serialization Coding Area

Please indicate the number of shipping labels that you need to return the recalled product(s): \_\_\_\_\_

Inmar/MedTurn Use Only:				
Scan	Labels	Store	Kit	D.B